Novo Nordisk said Thursday that the rampant growth of the U.S.' compounded drug industry was hurting Wegovy sales, and warned ...

Novo Nordisk said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial. The pill lowered the risk ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

Compounded versions could make up as much as 40% of the semaglutide market, said Novo Nordisk CEO Lars Fruergaard Jorgensen ...

Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and ...

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Researchers suggest the 20% reduction in nonfatal heart attacks was the primary driver of this benefit for patients with type ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...